Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo biloba in early age-related cognitive decline
NCT04121728Unknown
- Start
- Sep 2019
- Primary completion
- May 2024
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial of EGb 761 in subjective cognitive decline (SCD). Primary endpoint: Reproducibility of contingent negative variation (CNV) event-related potential (ERP) component amplitude at 14 months. Status: unknown.
02
Drugs
EGb 761
03
Conditions
subjective cognitive decline (SCD)
Beyond the preview
Go deeper on NCT04121728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121728.